RoslinCT is a leading global CDMO specializing in Advanced Cell and Gene Therapies. Founded in 2006, it leverages science from the cloning of Dolly the Sheep in 1997 to advance human medicine development. RoslinCT is one of the first to produce clinical-grade human pluripotent stem cells and supporting the development of therapies based on CRISPR-edited stem cell-based therapy. With 22 cGMP cell therapy processing suites, RoslinCT offers innovative PD/AD, cGMP manufacturing, and iPSC cell line development, gene editing and differentiation. The tailored CDMO solutions facilitate seamless progression from development to commercialization, delivering therapies globally.
www.roslinct.com